Overview

Fuzheng Yiliu-1010

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Real world study was used to evaluate the therapeutic effect of Fuzheng anti-tumor therapy on colorectal cancer patients in stage II and III after surgery and standard chemotherapy, and the prediction model of dominant population of Fuzheng anti-tumor therapy was constructed by using real-world data and gene expression profile data.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong Provincial Hospital of Traditional Chinese Medicine